Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant?

International Journal of Pharmaceutics

Volumn 390, Issue 1, 2010, Pages 32-36

  van den Berg, J H ^a,b   Quaak, S G L ^a   Beijnen, J H ^a,b   Hennink, W E ^b   Storm, G ^b   Schumacher, T N ^a   Haanen, J B A G ^a   Nuijen, B ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Dermal delivery; DNA tattooing; DNA vaccination; LPS

Indexed keywords

ANTIGEN; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; CORE PROTEIN; NUCLEOPROTEIN (366-374), INFLUENZA VIRUS; PEPTIDE FRAGMENT; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG CONTAMINATION; DRUG IMPURITY; GOOD MANUFACTURING PRACTICE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ANIMAL; BLOOD; C57BL MOUSE; CELLULAR IMMUNITY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; GENE EXPRESSION; IMMUNITY, CELLULAR; INJECTIONS, INTRADERMAL; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL CORE PROTEINS;

EID: 77951258523     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.06.031     Document Type: Article

References (36)

1. Backhed F., Normark S., Schweda E.K., Oscarson S., Richter-Dahlfors A. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes Infect. 2003, 5:1057-1063.
2. Bentala H., Verweij W.R., Huizinga-Van der Vlag A., Loenen-Weemaes A.M., Meijer D.K., Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002, 18:561-566.
3. Bins A.D., Jorritsma A., Wolkers M.C., Hung C.F., Wu T.C., Schumacher T.N., Haanen J.B. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 2005, 11:899-904.
4. Boyle J.S., Brady J.L., Koniaras C., Lew A.M. Inhibitory effect of lipopolysaccharide on immune response after DNA immunization is route dependent. DNA Cell Biol. 1998, 17:343-348.
5. Budryk M., Cichon T., Szala S. Direct in vivo transfer of plasmid DNA into murine tumors: effects of endotoxin presence and transgene localization. Acta Biochim. Pol. 2001, 48:795-800.
6. Copeland S., Warren H.S., Lowry S.F., Calvano S.E., Remick D. Acute inflammatory response to endotoxin in mice and humans. Clin. Diagn. Lab Immunol. 2005, 12:60-67.
7. European Pharmacopoeia, 6th Ed., 2008. European Pharmacopoeia Commission, Strasbourg, France.
8. Ferreira G.N., Monteiro G.A., Prazeres D.M., Cabral J.M. Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. Trends Biotechnol. 2000, 18:380-388.
9. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23:1804-1813.
10. Granucci F., Ferrero E., Foti M., Aggujaro D., Vettoretto K., Ricciardi-Castagnoli P. Early events in dendritic cell maturation induced by LPS. Microbes Infect. 1999, 1:1079-1084.
11. Harden L.M., du P.I., Poole S., Laburn H.P. Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol. Behav. 2006, 89:146-155.
12. Hawkins W.G., Trcka J., Segal N., Blachere N.E., Gold J.S., Moroi Y., Bowne W.B., Lewis J.J., Wolchok J.D., Houghton A.N. The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine 2003, 21:1548-1553.
13. Horn N.A., Meek J.A., Budahazi G., Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum. Gene Ther. 1995, 6:565-573.
14. Marquet M., Horn N.A., Meek J.A. Characterization of plasmid DNA vectors for use in human gene therapy, part 2. BioPharm 1997, 40-45.
15. Michelsen K.S., Aicher A., Mohaupt M., Hartung T., Dimmeler S., Kirschning C.J., Schumann R.R. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J. Biol. Chem. 2001, 276:25680-25686.
16. Miller A.M., Ozenci V., Kiessling R., Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J. Immunother. 2005, 28:389-395.
17. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., Georgiev G., Petrov S., Meryman H.T. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur. Urol. 2000, 38:208-217.
18. Montbriand P.M., Malone R.W. Improved method for the removal of endotoxin from DNA. J. Biotechnol. 1996, 44:43-46.
19. Nukina H., Sudo N., Aiba Y., Oyama N., Koga Y., Kubo C. Restraint stress elevates the plasma interleukin-6 levels in germ-free mice. J. Neuroimmunol. 2001, 115:46-52.
20. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., Bergman B., Egevad L., Hellstrom M., Kiessling R., Masucci G., Wersall P., Nilsson S., Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 2004, 91:688-694.
21. Poxon S.W., Hughes J.A. Characterization of endotoxin and cationic liposome interaction. Pharm. Dev. Technol. 1999, 4:135-143.
22. Przybylowski M., Bartido S., Borquez-Ojeda O., Sadelain M., Riviere I. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine 2007, 25:5013-5024.
23. Quaak S.G.L., van den Berg J.H., Toebes M., Schumacher T.N., Haanen J.B.A.G., Beijnen J.H., Nuijen B. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. Eur. J. Pharm. Biopharm. 2008, 70:429-438.
24. Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J., Gros P., Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 189:615-625.
25. Rosenberg S.A., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., White D.E. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum. Gene Ther. 2003, 20:709-714.
26. Sasaki S., Tsuji T., Hamajima K., Fukushima J., Ishii N., Kaneko T., Xin K.Q., Mohri H., Aoki I., Okubo T., Nishioka K., Okuda K. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect. Immun. 1997, 65:3520-3528.
27. Schalk, J.A.C., Hegger, I., Jongen, P.M.J.M., 2001. Gene therapeutics and DNA vaccines; quality and regulatory aspects. RIVM Report. National Institute for Public Health and Environment.
28. Schleef M., Schmidt T. Animal-free production of ccc-supercoiled plasmids for research and clinical applications. J. Gene Med. 2004, 6:S45-S53.
29. Thurnher M. Lipids in dendritic cell biology: messengers, effectors, and antigens. J. Leukoc. Biol. 2007, 81:154-160.
30. Timmerman J.M., Singh G., Hermanson G., Hobart P., Czerwinski D.K., Taidi B., Rajapaksa R., Caspar C.B., Van B.A., Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002, 62:5845-5852.
31. Toebes M., Coccoris M., Bins A., Rodenko B., Gomez R., Nieuwkoop N.J., van de K.W., Rimmelzwaan G.F., Haanen J.B., Ovaa H., Schumacher T.N. Design and use of conditional MHC class I ligands. Nat. Med. 2006, 12:246-251.
32. US Pharmacopeia, XXXII Ed., 2008. US Pharmacopeia Convention, Rockville, MD.
33. Verstrepen B.E., Bins A.D., Rollier C.S., Mooij P., Koopman G., Sheppard N.C., Sattentau Q., Wagner R., Wolf H., Schumacher T.N., Heeney J.L., Haanen J.B. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 2008, 26:3346-3351.
34. Weber M., Moller K., Welzeck M., Schorr J. Short technical reports. Effects of lipopolysaccharide on transfection efficiency in eukaryotic cells. Biotechniques 1995, 19:930-940.
35. Yoshizumi M., Nakamura T., Kato M., Ishioka T., Kozawa K., Wakamatsu K., Kimura H. Release of cytokines/chemokines and cell death in UVB-irradiated human keratinocytes, HaCaT. Cell Biol. Int. 2008, 32:1405-1411.
36. Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J.D., Wetsel R.A., Miwa T., Song W.C. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007, 110:228-236.